Daniel Brandeis Selected Research

Neurofeedback

1/2022	Personalized at-home neurofeedback compared to long-acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial.
10/2021	Can neurophysiological markers of anticipation and attention predict ADHD severity and neurofeedback outcomes?
1/2021	Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review.
3/2019	The impact of successful learning of self-regulation on reward processing in children with ADHD using fMRI.
1/2019	Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD.
8/2018	Informant-related effects of neurofeedback and cognitive training in children with ADHD including a waiting control phase: a randomized-controlled trial.
1/2018	Neurofeedback Training Effects on Inhibitory Brain Activation in ADHD: A Matter of Learning?
1/2018	Mixed-Effects Modeling of Neurofeedback Self-Regulation Performance: Moderators for Learning in Children with ADHD.
1/2017	Real-time fMRI neurofeedback in adolescents with attention deficit hyperactivity disorder.
1/2017	Neurofeedback of Slow Cortical Potentials in Children with Attention-Deficit/Hyperactivity Disorder: A Multicenter Randomized Trial Controlling for Unspecific Effects.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Brandeis Research Topics

Disease

43	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2022 - 07/2007
6	Autism Spectrum Disorder 01/2021 - 01/2017
4	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2021 - 11/2017
3	Mental Disorders (Mental Disorder) 11/2018 - 01/2016
2	Conduct Disorder (Conduct Disorders) 12/2019 - 03/2003
2	Autistic Disorder (Autism) 01/2017 - 01/2017
2	Schizophrenia (Dementia Praecox) 03/2016 - 01/2016
2	Anxiety Disorders (Anxiety Disorder) 01/2015 - 06/2014
2	Dyslexia (Alexia) 08/2011 - 08/2009
1	Attention Deficit and Disruptive Behavior Disorders (Disruptive Behavior Disorder) 01/2022
1	Depressive Disorder (Melancholia) 01/2019
1	Traumatic Brain Injuries (Traumatic Brain Injury) 12/2017
1	Acquired Immunodeficiency Syndrome (AIDS) 05/2016
1	Bipolar Disorder (Manic Depressive Psychosis) 09/2015

Drug/Important Bio-Agent (IBA)

6	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2016
6	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 12/2017 - 03/2003
5	Methylphenidate (Ritalin)FDA LinkGeneric 01/2022 - 04/2014
5	Glutamic Acid (Glutamate)FDA Link 01/2021 - 11/2017
3	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 09/2015 - 06/2014
2	Pharmaceutical PreparationsIBA 01/2022 - 05/2016
1	Polymethyl Methacrylate (Sol)IBA 11/2021
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2021
1	BuffersIBA 11/2018
1	N-acetylaspartate (N-acetyl aspartate)IBA 01/2018
1	Neurotransmitter Agents (Neurotransmitter)IBA 12/2017
1	Dopamine (Intropin)FDA LinkGeneric 01/2016
1	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 04/2015
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 08/2014
1	Dopamine Receptors (Dopamine Receptor)IBA 08/2014
1	SmokeIBA 07/2014
1	Hemoglobins (Hemoglobin)IBA 01/2014
1	Nonesterified Fatty Acids (NEFA)IBA 03/2013
1	PlasticsIBA 08/2011
1	Complement System Proteins (Complement)IBA 08/2009

Therapy/Procedure

23	Neurofeedback 01/2022 - 07/2007
7	Cognitive Training 08/2019 - 03/2013
3	Psychology Biofeedback (Biofeedback) 03/2019 - 01/2014
2	Combined Modality Therapy 04/2018 - 01/2018
2	Electrodes (Electrode) 07/2015 - 01/2013
1	Transcranial Direct Current Stimulation 01/2021
1	Therapeutics 04/2018